SRR10900563
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.300
- SPERMATOGENESIS+0.300
- E2F_TARGETS+0.200
- MYC_TARGETS_V1+0.200
- G2M_CHECKPOINT+0.100
- ADIPOGENESIS-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- FATTY_ACID_METABOLISM-0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.600
- APOPTOSIS-0.500
- NOTCH_SIGNALING-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ALLOGRAFT_REJECTION-0.400
- ANGIOGENESIS-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.917 |
| 2 | sclc0624_S64.txt | — | cohortSC | 0.896 |
| 3 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.888 |
| 4 | SRR10899998 | — | — | 0.879 |
| 5 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.878 |
| 6 | ERR3262565 | — | — | 0.873 |
| 7 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.872 |
| 8 | BS_W9AT0MR7 | medulloblastoma | — | 0.872 |
| 9 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.872 |
| 10 | SRR8526719 | — | cohortMD1 | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |